Sotorasib for Lung Cancers with KRAS p.G12C Mutation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34096690/
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Key Points
• In the current Phase 2 trial published in NEJM, investigators assessed the activity of sotorasib (960 mg PO qd) in patients with KRAS –mutated advanced NSCLC who were previously treated with standard therapies.
• Overall, ORR was exhibited in 46 of 124 patients, with 4 demonstrating complete response and 42, partial response. The median duration of response was 11.1 months, with a median PFS of 6.8 months and a median OS of 12.5 months. Disease control was exhibited in 100 patients.
• Subgroups of patients with PD-L1 expression, tumor mutational burden, and co-occurring mutations in STK11, KEAP1, or TP53 responded to treatment.
• “In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS –mutated NSCLC,” the authors concluded.